Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aliskiren
Drug ID BADD_D00073
Description Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.[L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]
Indications and Usage For the treatment of hypertension, to lower blood pressure.
Marketing Status Prescription
ATC Code C09XA02
DrugBank ID DB09026
KEGG ID D03208
MeSH ID C446481
PubChem ID 5493444
TTD Drug ID D03SVX
NDC Product Code 49884-425; 49884-424
Synonyms aliskiren | rasilez | Tekturna | CGP 060536B | CGP060536B | CGP-060536B | 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate | SPP100
Chemical Information
Molecular Formula C30H53N3O6
CAS Registry Number 173334-57-1
SMILES CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.001--
Septic shock24.06.02.011; 11.01.11.0040.000729%Not Available
Skin disorder23.03.03.007--Not Available
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.0030.002793%Not Available
Stevens-Johnson syndrome12.03.01.014; 11.07.01.005; 10.01.03.020; 23.03.01.007--
Sudden death08.04.01.003; 02.03.04.0130.000729%
Swelling08.01.03.015--Not Available
Swelling face23.04.01.018; 10.01.05.0180.002793%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.008378%
Tachycardia02.03.02.0070.002793%Not Available
Thrombosis24.01.01.0060.002793%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Transient ischaemic attack24.04.06.005; 17.08.04.0010.006982%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.002793%
Ventricular tachycardia02.03.04.0100.005586%
Vertigo17.02.12.002; 04.04.01.0030.002793%
Vision blurred17.17.01.010; 06.02.06.0070.002793%
Visual acuity reduced17.17.01.011; 06.02.03.0010.002793%
Vomiting07.01.07.0030.008378%
Weight decreased13.15.01.0050.004189%
Weight increased13.15.01.0060.002793%
Mobility decreased17.02.05.018; 15.03.01.003; 08.01.03.0300.002793%Not Available
Sudden cardiac death02.03.04.016; 08.04.01.0080.001093%Not Available
Left ventricular dysfunction02.04.02.0110.002793%
Bradyarrhythmia02.03.02.0150.002793%Not Available
Left ventricular hypertrophy02.04.02.0140.002793%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages